IBSA
2.2.2024 14:33:26 CET | Business Wire | Press release
After a thorough overhaul in the shipyard to prepare the boat for the 2024 transoceanic races, the third season of the Class40 IBSA will start with two monumental tests, scheduled between April and July. As holder of first place in the international Class40 Circuit and the 24-hour Class40 distance record, both achieved during the 2023 season, Alberto Bona is getting ready to participate in the Transat CIC, to be held between April and May, and in the Transat Québec Saint-Malo, scheduled between June and July, to then complete the season with the Normandy Channel Race.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240202006265/en/
“We called it the season of courage”, stated Giorgio Pisani, Vice President IBSA Group and Leader of the project Sailing into the Future. Together. “But it will also be the season of maturity, for both Alberto and our project. In 2023 we achieved great sporting results, but also human ones, thanks to the commitment, consistency and resolution in completing the objectives we had set for ourselves. The 2024 season promises to be exciting: behind us, we have the experience that we strategically need to best manage the planned programme, while in our hearts is the courage to face any challenge, with the enthusiasm of the first day”.
“This third season with the Class40 IBSA”, commented Bona, “opens with a legendary regatta. I have enormous respect for this course, which I have never done; it’s a new challenge for me: a challenging route in the North Atlantic, in the first months of the season, very difficult due to wind, sea and current conditions. We are making some changes to the boat, in order to be best prepared for this first solo transoceanic. It’s important work”, continued Alberto, “which requires time and accurate assessments. On paper, it’s the most difficult regatta I have ever done. A beautiful adventure, also for IBSA, with a season that will take us to America and on less travelled routes; a season which I hope will be greatly satisfactory for everyone. I used to dream with the great navigators’ stories of the OSTAR, and I didn’t think that one day I would be able to do it myself... especially with a Class40!”.
The season will begin on April 28, with the Transat CIC, the new name of the oldest transoceanic regatta, the first edition of which took place in 1960. Then it was called the OSTAR; later it was renamed 1 Star and today is simply known as The Transat. Legendary names in ocean sailing have won it, from Sir Francis Chichester to Eric Tabarly. “This Transat is also the regatta in which the world discovered the great talent of Ellen MacArthur, who made her debut at just 23 years of age in this very difficult race”, recalled Bona. “It’s a solo regatta for which I have great expectations. I’m happy to go back to solo sailing after a season spent entirely with a crew. After the 2022 Route du Rhum, finding myself alone on the Class40 IBSA with so much more experience and knowledge of the boat is a great challenge”.
Anticipation is huge, after the 2020 edition was cancelled due to the pandemic: the regatta will therefore start again from the 15th edition, eight years after the previous one. The race will depart from Lorient, Brittany, on April 28 (the village will start celebrating on April 23), and arrive in New York, after over 3,000 miles of solo sailing. There will be a maximum of 80 boats at the start: 25 Class40s, 35 IMOCAs, 10 Ocean Fiftys and 10 vintage sailing boats, with registrations closing on January 31. The Class40 IBSA is automatically qualified, thanks to her participation in the 2022 Route du Rhum.
Sailing under the Statue of Liberty will certainly be a great thrill, as will be carrying the Class40 IBSA even further north, up to Canada, with an unforgettable 1,200 mile journey that will lead to the second, and equally legendary, challenge – the Transat Quebec Saint-Malo, one of the few Atlantic regattas sailed “in reverse”, from West to East, crossing the Northern waters and navigating for over 300 miles along a river, the St. Lawrence, in Canada. Now in its 10th edition – it also did not take place four years ago, due to COVID – and dedicated to the Ultim, Class40, IMOCA, Ocean Fifty and Mono and multihull categories between 45 and 65 feet, the Québec Saint-Malo is a regatta for a crew of three. Sailors will start on June 30 and – after dealing with the waters of the North Atlantic – will land in Saint-Malo, where three years ago everything began for the Class40 IBSA, with the departure for the Route du Rhum.
“After the Quebec Saint-Malo”, concluded Alberto, “we will be back in the La Trinité shipyard to get ready for the last event of the year, the Normandy Channel Race. These three regattas will, I hope, allow us to defend our Class40 championship title. It will be another challenging season for everyone, with thousands of miles behind and hopefully with more good results”.
THE PROJECT: The three-year project Sailing into the Future. Together was launched in January 2022. The partnership between IBSA and skipper Alberto Bona was born on common bases and values, and aims to use sailing as a corporate communication vehicle towards the market and the nautical world. Ingenuity, courage, innovation, responsibility are elements that unites IBSA and Alberto, and the oceanic challenge, in addition to the sporting competition, also metaphorically represents the company’s history, philosophy and vision, which are always oriented towards and are part of a path that brings IBSA increasingly closer to the topic of environmental and social sustainability, with a particular focus on inclusive sailing projects for people with disabilities. In November 2022, the Route du Rhum was the first sporting stage of the project Sailing into the Future. Together. In 2023, Bona and the Class40 IBSA participated in six regattas, including the Rolex Fastnet Race and the Transat Jacques Vabre. With two victories and three podiums, the record for the highest number of miles covered in 24 hours and over 15,000 miles sailed, Bona won first place overall in the Class40 International Championship. In 2024, between April and July, he will face two of the toughest transatlantic races on the international scene: the Transat CIC from Lorient (France) to New York and the Quebec Saint-Malo (from Canada to France). |
|
THE SKIPPER: Alberto Bona is from Turin, and has a degree in philosophy. As a university student, he won the Panerai trophy aboard Stormvogel, fast ULDB and historic boat with which he crossed the Atlantic Ocean for the first time, winning the ARC with a New Zealand crew. In 2012 he took part in the Minitransat, finishing 5th, one of the best Italian results ever in this category. In 2015, he switched to the prototype category Mini 6.50 with Promostudi La Spezia: he won the Italian championship and finished second in the ocean crossing Les Sables-Azores. In 2017 he discovered the Class40: on Giovanni Soldini’s former Telecom Italia, he participated in the Transat Jacques Vabre, where he was forced to withdraw when he was in sixth place. In 2019 he was aboard the Maserati Multi 70 trimaran, one of the world’s fastest boats, where he practiced on the foils before moving on to the Figaro Beneteau 3, aboard which he participated in the Solitaire; the only Italian registered, in 2020 he finished 7th among the rookies in the first year and 16th overall. In 2021 he won the Italian offshore team title and the Europeans in mixed doubles aboard the Figaro 3. In 2022 he started the new project in partnership with IBSA: after an eighth place in the Route du Rhum 2022, in 2023 Alberto won the Class40 International Championship, closing a season with three podiums and over 15,000 miles covered. |
|
THE BOAT: Designed by French naval architect Sam Manuard and built by the JPS Production shipyard, Alberto Bona’s boat is a Class40 Mach 5 model. Its main characteristics are: scow bow – rounded and with a wider and flatter shape than standard bows – designed to stay high above the water and avoid being submerged; all-round hull, particularly performing in conditions of strong tailwinds; and a large, shielded cockpit, to face extreme conditions of navigation in as comfortable and safe as possible positions. |
|
IBSA: IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 countries on 5 continents, through the Company’s 18 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 900 million CHF, and employs over 2,200 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility. |
For more information visit www.ibsasailing.com/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202006265/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom